We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+47.61%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.49B
AUM Growth
+$63.7M
Cap. Flow
-$72.5M
Cap. Flow %
-4.85%
Top 10 Hldgs %
49.88%
Holding
81
New
8
Increased
11
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$22.9M
2
AXSM icon
Axsome Therapeutics
AXSM
+$19.4M
3
PRME icon
Prime Medicine
PRME
+$13.3M
4
PCVX icon
Vaxcyte
PCVX
+$12.8M
5
BCAB icon
BioAtla
BCAB
+$12.4M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$38.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$27.9M
3
ACLX
Arcellx
ACLX
+$22.3M
4
ACET icon
Adicet Bio
ACET
+$12.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
26
Amylyx Pharmaceuticals
AMLX
$2.54B
$20.3M 1.36%
550,000
-60,000
-10% -$2.13M
AXNX
27
DELISTED
Axonics, Inc. Common Stock
AXNX
$20.1M 1.35%
322,240
– –
CABA icon
28
Cabaletta Bio
CABA
$455M
$18.2M 1.22%
1,971,739
+817,315
+71% +$2.98M
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.1M 1.21%
400,000
-175,000
-30% -$11.3M
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$394M
$17M 1.14%
868,550
– –
PCVX icon
31
Vaxcyte
PCVX
$8.64B
$15.6M 1.04%
+325,000
New +$12.8M
PLRX icon
32
Pliant Therapeutics
PLRX
$65M
$15.1M 1.01%
782,788
– –
PRME icon
33
Prime Medicine
PRME
$556M
$13.6M 0.91%
+734,350
New +$13.3M
CYTK icon
34
Cytokinetics
CYTK
$10.4B
$13.6M 0.91%
296,000
– –
IMRX icon
35
Immuneering
IMRX
$292M
$11.1M 0.74%
2,286,181
– –
GRNA
36
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$10.8M 0.73%
9,188,659
-1,072,901
-10% -$1.75M
BBIO icon
37
BridgeBio Pharma
BBIO
$16.5B
$10.4M 0.7%
1,369,179
-100,000
-7% -$957K
COGT icon
38
Cogent Biosciences
COGT
$7.24B
$10.4M 0.7%
900,000
-550,000
-38% -$6.82M
STOK icon
39
Stoke Therapeutics
STOK
$2.11B
$10M 0.67%
1,087,807
– –
ARQT icon
40
Arcutis Biotherapeutics
ARQT
$3.18B
$9.62M 0.64%
650,000
-350,000
-35% -$6.11M
PHVS icon
41
Pharvaris
PHVS
$2.44B
$9.19M 0.61%
816,460
-391,040
-32% -$2.06M
VIGL
42
DELISTED
Vigil Neuroscience
VIGL
$7.71M 0.52%
616,786
– –
AVIR icon
43
Atea Pharmaceuticals
AVIR
$420M
$7.44M 0.5%
1,547,181
– –
IMVT icon
44
Immunovant
IMVT
$8.25B
$7.1M 0.48%
+400,000
New +$5.04M
LBPH
45
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$6.91M 0.46%
2,118,283
– –
ALXO icon
46
ALX Oncology
ALXO
$283M
$6.9M 0.46%
612,079
-100,000
-14% -$1.12M
VERV
47
DELISTED
Verve Therapeutics
VERV
$6.77M 0.45%
350,000
-250,000
-42% -$6.62M
ALT icon
48
CALL
Altimmune
ALT
$599M
$6.58M 0.44%
+400,000
New +$4.49M
VKTX icon
49
Viking Therapeutics
VKTX
$4B
$6.58M 0.44%
+700,000
New +$3.12M
IDYA icon
50
IDEAYA Biosciences
IDYA
$3.56B
$6.36M 0.43%
350,000
-68,320
-16% -$1.15M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Cormorant Asset Management held 81 positions worth $1.49B, up 4.5% from $1.43B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $72.5M in Q4 2022, closing 8 positions and reducing 24 holdings. Its most notable exit was Gossamer Bio, an estimated $38.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in 89bio worth $32.5M.

  • Cormorant Asset Management's largest Q4 2022 buy was 89bio: 2,550,000 shares worth $32.5M.
  • Cormorant Asset Management added most to BioAtla in Q4 2022, an estimated $12.4M increase.
  • Cormorant Asset Management's biggest Q4 2022 reduction was Arcellx, cutting an estimated $22.3M.
  • Cormorant Asset Management fully exited Gossamer Bio in Q4 2022, selling an estimated $38.3M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.49B portfolio in Q4 2022.
  • Cormorant Asset Management opened 8 new positions and closed 8 in Q4 2022.
  • Cormorant Asset Management's portfolio value rose 4.5% quarter-over-quarter to $1.49B.

Based on Cormorant Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.